Health advocacy groups called on the European Commission to change the way it funds research and development for new medicines so that innovations can serve a larger public.
The call from eight civil society groups comes following the Commission’s public consultation for the mid-term review of the European Union’s research and innovation programme, Horizon 2020 (H2020), which administers a funding pool of nearly €80 billion, according to a press release.
The groups co-authored a submission to the H2020 consultations with several recommendations. The submission was endorsed by another 16 groups.
Recommendations included improving public health needs-driven priority setting for biomedical R&D, ensuring public return on public investment and safeguard equitable access to publicly funded health technologies, and increasing transparency of research consortium agreements.
“At a time when there is real concern within Member States over astronomical prices for new drugs treating cancer and hepatitis C, the European Commission has the opportunity to take real and practical steps to make new biomedical discoveries affordable and accessible across the European Union,” said Aliénor Devalière of Médecins Sans Frontières – Access Campaign, one of the report’s authors.